Clinical trials: Plaque, Amyloid
Alzheimer's Disease
Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease
The overall goal of this double-blind Phase II study is to evaluate the safety, efficacy and biological mechanisms of action of Intravenous Immunoglobulin (IVIg) in the treatment of mild to moderate stage Alzheimer's disease…
- Trial name
- NCT00299988
- Testing
- Intravenous Immunoglobulin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Weill Medical College of Cornell University
Gingival Inflammation, Plaque
The Effectiveness of Brushing and Flossing Sequence on Control of Plaque and Gingival Inflammation
This study evaluates the effectiveness of brushing and flossing sequence in the control of dental plaque and gingival inflammation.
- Conditions
- Gingival Inflammation, Plaque, Gingival Bleeding, Plaque Control
- Trial name
- RCT (NCT03989427)
- Testing
- Brushing first and Flossing later (BF), Flossing first and Brushing later (FB)
- Where
- Malaysia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Melaka Manipal Medical College
Plaque, Gingivitis
Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population
This study is to assess the safety and tolerability of single doses and multiple doses in reducing plaque and gingivitis when delivered in a chewing gum formulation.
- Trial name
- APCG (NCT01877421)
- Testing
- 2 mg KSL-W, 4 mg KSL-W, 6 mg KSL-W
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Moderate to Severe Palmoplantar Psoriasis
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis
Purpose of the study was to demonstrate the efficacy of secukinumab versus placebo on palmoplantar psoriasis and to assess the long term efficacy, safety and tolerability of secukinumab.
- Trial name
- GESTURE (NCT01806597)
- Testing
- secukinumab 150 mg, secukinumab 300 mg
- Where
- 54 sites in United States, Australia and 13 more
- Volunteers
- 205 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis
The purpose of this study is 1) to determine whether Imiquimod or Steroid pretreatment modifies UVB laser light response resulting in increased cell death compared to UVB laser light alone; 2) to determine if pretreatment of…
- Trial name
- NCT00470392
- Testing
- Imiquimod, Clobetasol
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- VA Office of Research and Development
Moderate to Severe Plaque-type Psoriasis
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- ERASURE (NCT01365455)
- Testing
- secukinumab 150 mg
- Where
- 88 sites in United States, Argentina and 10 more
- Volunteers
- 738 people
- Sponsor
- Novartis Pharmaceuticals
Mild Cognitive Impairment
Candesartan's Effects on Alzheimer's Disease And Related Biomarkers
This study is intended to investigate the safety of candesartan, a blood pressure medication, in non-hypertensive individuals who have mild cognitive impairment (MCI) due to Alzheimer's disease and its effect on disease…
- Trial name
- CEDAR (NCT02646982)
- Testing
- Candesartan
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- Emory University
Dental Plaque
Evaluating the Effect of Tooth Cleaning Devices on Oral Health
This is a study to evaluate the safety and the efficacy of tooth and interproximal cleaning modalities on oral health.
- Trial name
- NCT01250769
- Testing
- Manual Toothbrush, Interproximal Cleaning Device
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- Philips Oral Healthcare
Psoriasis
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
Evaluate psoriasis severity and its psychosocial impact using a novel Patient Reported Outcome (the Simplified Psoriasis Index SPI) at 16 weeks, as well as long-term safety, tolerability and efficacy of secukinumab administered…
- Trial name
- IPSI-PSO (NCT02595970)
- Testing
- Secukinumab
- Where
- 17 sites in France
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Plaque-type Psoriasis
Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens
This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- SCULPTURE (NCT01406938)
- Testing
- AIN457 150mg, AIN457 300mg
- Where
- 131 sites in United States, Austria and 14 more
- Volunteers
- 967 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)
The purpose of this study is to evaluate radiolabeled [18F]MK-3328 as a PET tracer for estimating the regional distribution and extent of amyloid plaques in participants suffering from amnestic mild cognitive impairment (aMCI)…
- Trial name
- NCT01385033
- Testing
- [18F]MK-3328
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis, Metabolic Syndrome
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
This study was a randomized, open-label, parallel-group, active comparator controlled study with two treatment arms designed to answer the question whether the combination of Secukinumab with lifestyle intervention could…
- Trial name
- METABOLYX (NCT03440736)
- Testing
- Secukinumab, Life-style intervention
- Where
- 75 sites in Germany
- Volunteers
- 781 people
- Sponsor
- Novartis Pharmaceuticals
Peripheral Artery Disease, Atherosclerosis
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
To evaluate the safety and effectiveness of the Ranger™ Paclitaxel Coated Balloon for treating lesions located in the superficial femoral and proximal popliteal arteries (SFA/PPA).
- Conditions
- Peripheral Artery Disease, Atherosclerosis, Artery Diseases, Peripheral, Plaque, Atherosclerotic
- Trial name
- RANGER II SFA (NCT03064126)
- Testing
- RANGER™ Paclitaxel Coated Balloon, Paclitaxel, Standard Balloon Angioplasty
- Where
- 67 sites in United States, Austria and 4 more
- Volunteers
- 440 people
- Sponsor
- Boston Scientific Corporation
Gingivitis
Comparative Efficacy of a Toothpaste That Reduces Plaque and Gingivitis
The objective of this study is to evaluate the performance of two toothpastes in controlling established gingivitis and dental plaque in adults.
- Trial name
- NCT00926328
- Testing
- Triclosan, fluoride, Fluoride
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Amyloid-beta
Sleep Quality and Amyloid-Beta Kinetics
The purpose of this study is to change the concentration of amyloid-beta in human cerebrospinal fluid (CSF) by modification of sleep efficiency.
- Trial name
- NCT03077620
- Testing
- Suvorexant
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Obstructive Coronary Artery Disease, Coronary Artery Disease
YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering
Coronary artery disease (CAD) remains a leading cause of death in most countries. It is well known that the reduction of cholesterol levels by statin therapy is associated with significant decreases in plaque burden.
- Trial name
- NCT01837823
- Testing
- rosuvastatin
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alzheimer Disease, Amyloid Beta-Protein
Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers
The aim of this study is to evaluate the efficacy, safety of a single dose of BAY 94-9172 (ZK 6013443) as an investigational medicinal product (IMP) in detecting cerebral protein-plaque (amyloid beta) with positron emission…
- Trial name
- NCT00750282
- Testing
- Florbetaben (BAY94-9172)
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 422 people
- Sponsor
- Lantheus Biosciences Ltd.
Plaque Psoriasis
Plaque Psoriasis Efficacy and Safety With Secukinumab
To demonstrate in the patient pool of PASI 90 responders at Week 24 that secukinumab 300 mg s.c. when administered at a longer dosing interval is non-inferior to secukinumab 300 mg s.c.
- Trial name
- OPTIMISE (NCT02409667)
- Testing
- Secukinumab
- Where
- 200 sites in Austria, Belgium and 22 more
- Volunteers
- 16,487 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease, Amyloid Beta-Protein
Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients
The aim of the study is to investigate whether Florbetaben (BAY94-9172)positron emission tomography (PET) is able to distinguish between subjects with mild cognitive impairment (MCI) progressing to Alzheimer's disease (AD) from…
- Trial name
- NCT01138111
- Testing
- Florbetaben (BAY94-9172)
- Where
- Australia
- Volunteers
- 45 people
- Sponsor
- Lantheus Biosciences Ltd.
Chronic Traumatic Encephalopathy
Tau Imaging of Chronic Traumatic Encephalopathy
Chronic traumatic encephalopathy (CTE) is a progressive degenerative brain disease with symptoms that include memory loss, problems with impulse control, and depression that can lead to suicide.
- Trial name
- NCT02191267
- Testing
- [F18]-T807, [F18]-Florbetapir, MRI/MRS
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital